Comparative Pharmacology
Head-to-head clinical analysis: IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE versus LODINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE versus LODINE.
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE vs LODINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Phenylephrine is a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
1 tablet (ibuprofen 200 mg/phenylephrine HCl 10 mg) orally every 4-6 hours as needed, not to exceed 6 tablets per 24 hours.
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
None Documented
None Documented
Ibuprofen: 2-4 hours (prolonged in overdose or hepatic impairment). Phenylephrine: 2-3 hours (clinical activity may persist longer due to vasoconstrictive effects).
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
Ibuprofen: Renal elimination of metabolites (90%) and unchanged drug (1-10%); biliary/fecal excretion minor. Phenylephrine: Renal elimination (80-85% as inactive metabolites, 2-3% unchanged); biliary/fecal negligible.
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Category D/X
Category C
NSAID
NSAID